|
|
|
Originator Org.- |
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.DE |
First Approval Date01 Jan 1966 |
DESENSITIZE-PD: Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Support Dopaminergic Desensitization in Parkinson's Disease
20 patients with idiopathic Parkinson's disease, who are planned to undergo intestinal L-Dopa + entacapone (Lecigon®) treatment will be included into this observational single-armed study. These patient will be observed for hyperdopaminergic complications and neuropsychiatric fluctuations postprocedure at 3, 6 and 12 months.
Study on the incidence of genetic polymorphism in patients with major depression who are treated unsatisfactory with antidepressants - GENADET
100 Clinical Results associated with STADAPHARM GmbH
0 Patents (Medical) associated with STADAPHARM GmbH
100 Deals associated with STADAPHARM GmbH
100 Translational Medicine associated with STADAPHARM GmbH